Core Viewpoint - Edding Group Company Limited is set to reverse merge with Jiahe Biotech-B (06998.HK) through a share swap, marking Hong Kong's first reverse merger of an unprofitable biotech company under the 18A rule [3][5]. Group 1: Company Overview - Edding Group is a comprehensive biopharmaceutical company that has established a competitive portfolio of innovative drugs through acquisitions and licensing agreements with multinational pharmaceutical companies [5]. - The company has successfully launched multiple innovative drugs in China over its 20 years of operation, demonstrating strong clinical development and management capabilities [5]. - Edding's product portfolio includes five main products, three of which are original research products and two are innovative products, all of which have been commercialized [5][6]. Group 2: Financial Performance - Edding's revenue for the years 2022, 2023, 2024, and the first half of 2025 was RMB 2.073 billion, RMB 2.304 billion, RMB 2.546 billion, and RMB 1.136 billion respectively, with corresponding net profits of RMB 306 million, RMB 308 million, RMB 389 million, and RMB 115 million [17][18]. - The gross profit margin for the years 2022 to 2025 remained relatively stable, with gross profits of RMB 1.368 billion (66.0%), RMB 1.506 billion (65.4%), RMB 1.716 billion (67.4%), and RMB 760 million (66.9%) [18]. Group 3: Shareholder Structure - Prior to the merger, the controlling shareholder, Mr. Ni Xin, held 45.19% of the voting rights through various entities [10][11]. - Post-merger, Mr. Ni is expected to become the controlling shareholder of Edding Jiahe, with an estimated holding of approximately 37.39% [10][11]. Group 4: Management Team - The expanded board of directors will consist of seven members, including two executive directors, two non-executive directors, and three independent directors, effective upon completion of the merger [14][15]. - Key executives include Dr. Guo Feng as CEO and Dr. Han Shuhua as Chief Scientific Officer [15].

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內容而 引致的任何損失承擔任何責任。 a a a a a a a a a a a a a a a a GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （「本公司」） （於開曼群島註冊成立的有限公司） （股份代號：6998） 的聆訊後資料集 警告 閣下如已將名下之嘉和生物藥業（開曼）控股有限公司股份全部售出或轉讓，應立即將本通函連同隨附之代表委任表格，送交買主或承讓 人或經手買賣或轉讓之銀行、股票經紀或其他代理，以便轉交買主或承讓人。 本通函僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 a a a a a a a a a a a a a a a a GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作向香港 ...

Core Viewpoint - The China Securities Regulatory Commission has confirmed the overseas listing applications for five companies, all of which are seeking to list in Hong Kong [1] Group 1: Company Summaries - **Lemo**: Plans to issue up to 19,166,700 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Lemo is a machine massage service provider with over 48,000 service points and more than 535,000 massage machines deployed as of July 18, 2025. Revenue for 2022 to 2024 is projected at 330 million, 587 million, and 798 million CNY, with corresponding net profits of 6.48 million, 87.34 million, and 85.81 million CNY [3][5] - **Dipu**: Plans to issue up to 115,000,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Dipu focuses on providing AI solutions, including big data analysis and enterprise-level model applications, across various sectors. Revenue for 2022 to 2024 is projected at 100 million, 129 million, and 243 million CNY, with corresponding net losses of 655 million, 503 million, and 1.255 billion CNY [5][7] - **Red Star Cold Chain**: Plans to issue up to 26,752,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Red Star Cold Chain operates a platform for frozen food trading and storage services. Revenue for 2022 to 2024 is projected at 237 million, 202 million, and 234 million CNY, with corresponding net profits of 79 million, 75 million, and 83 million CNY [7][9] - **Sailis**: Plans to issue up to 331,477,235 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Sailis is a technology-driven automotive company focused on electric vehicles, having launched several models. Revenue for 2022 to 2024 is projected at 34.1 billion, 35.8 billion, and 145.1 billion CNY, with corresponding net losses of 5.2 billion, 4.2 billion, and a net profit of 4.7 billion CNY [9][11] - **Yiteng Pharmaceutical**: Plans to achieve a listing on the Hong Kong Stock Exchange through a merger with Genor Biopharma Holdings Limited, which will issue up to 1,883,972,094 ordinary shares. Yiteng focuses on the R&D, production, and commercialization of biopharmaceutical products across various therapeutic areas. Revenue for 2022 to 2024 is projected at 2.073 billion, 2.304 billion, and 2.546 billion CNY, with corresponding net profits of 306 million, 308 million, and 388 million CNY [11]

合并后公司拥有以景助达及GB491治疗晚期或转移性HR+/HER2-乳腺癌的协同专营权。 本文为IPO早知道原创 嘉和生物向亿腾医药股东发行新股作为对价， 亿腾医药、嘉和生物在此次交易中的股权价值分别为 6.77亿美元和1.97亿美元。 亿腾医药股东将持有 合并公司 77.43%的股份，成为 合并公司的 控股 股东，而嘉和生物的股东则持有 其余 的 22.57%股份。 亿腾医药 从一家 CSO发展成综合型生物医药公司， 专注于在中国研究、开发及商业化具有巨大市 场需求的治疗药物。公司通过向跨国公司收购品牌药物资产，以及从全球生物制药公司授权引进创新 专利药物的开发及商业化权利，已建立多元化产品组合 ， 主要覆盖 抗感染、 CVD及呼吸系统 疾病 。 其主要产品包括 3 款 原研药 稳可信、希刻劳 、 亿瑞平 、 2款创新药 Vascepa 、 Mulpleta ， 及 其他产品包括 H景助达、罗可曼均已经实现商业化。 同时 ，亿腾 医药通过 获得跨国公司转让生产设施及管理体系并实施运营，拥有了 符合国际标准 的 制造、供应链管理、技术转移及质量控制体系。 公司在中国 31个省份拥有1000名销售代表，覆盖约1 ...

Core Viewpoint - Jiayou Bio-B (06998) has submitted a listing application to the Hong Kong Stock Exchange, marking the first reverse acquisition case of an innovative pharmaceutical company since the implementation of Rule 18A by the Hong Kong Stock Exchange [1] Group 1: Company Overview - Yiteng Pharmaceutical is a comprehensive professional biopharmaceutical company that has established a competitive and market-potential portfolio of original and innovative drugs through acquisitions of brand drug assets from multinational companies [1] - The product portfolio of Yiteng Pharmaceutical includes five main products, three of which are original products (Wenkexin, Xikelai, and Yirui Ping) and two innovative products (Vascepa and Mulpleta), all of which have been commercialized [1][2] Group 2: Financial Performance - Yiteng Pharmaceutical's revenue for the years ending December 31, 2022, 2023, and 2024 is projected to be 2.0738 billion, 2.3038 billion, and 2.5460 billion respectively, indicating steady sales growth driven by the strong performance and potential of its product portfolio [5] Group 3: Strategic Implications - The integration of Jiayou Bio's innovative R&D resources will enable Yiteng Pharmaceutical to accelerate the development and market promotion of innovative drugs, particularly the upcoming CDK4/6 inhibitor, which can synergize with Yiteng's existing HDAC inhibitor to explore broader market opportunities [5]